Company Filing History:
Years Active: 2011
Title: David Jaramillo: Innovator in Sequence Selective Compounds
Introduction
David Jaramillo is an accomplished inventor based in Arncliffe, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of sequence selective compounds. His work focuses on targeting therapeutic and diagnostic groups to polynucleotides, which has important implications for medical research and treatment.
Latest Patents
David Jaramillo holds a patent for "Sequence selective pyrrole and imidazole polyamide metallocomplexes." This invention relates to sequence selective compounds designed for targeting therapeutic or diagnostic groups to polynucleotides. More specifically, it addresses the sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.
Career Highlights
David Jaramillo is affiliated with the University of Western Sydney, where he continues to advance his research and innovation in the field. His work has garnered attention for its potential applications in medicine and diagnostics.
Collaborations
Some of his notable coworkers include Craig Brodie and Warren Howard, who have collaborated with him on various projects related to his research.
Conclusion
David Jaramillo's innovative work in sequence selective compounds showcases his commitment to advancing biotechnology. His contributions have the potential to significantly impact therapeutic and diagnostic approaches in medicine.